RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights

RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The 300-patient Phase 2 study received FDA clearance and is estimated to be completed by the end of 2024

Read more at prnewswire.com